Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
Ironwood Pharmaceuticals amends a prior report to detail compensation for Ronald Silver in his new role as interim chief financial officer and principal financial officer. Effective with this role, the board’s Compensation and HR Committee approved a monthly interim assignment fee of $12,250 for Mr. Silver.
On May 19, 2026, Mr. Silver also received a grant of 25,000 restricted stock units under the 2019 Amended and Restated Equity Incentive Plan. These RSUs will vest over two years, with 50% vesting on each approximate anniversary of the grant date, aligning the interim CFO’s pay more closely with the company’s share performance.
Silver Ronald reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC executive Ronald Silver, who serves as PFO & PAO, received a grant of 25,000 shares of Common Stock in the form of restricted stock units. The award was granted at a price of $0.00 per share as equity compensation.
The restricted stock unit award vests in two equal installments, with 50% of the underlying Class A Common Stock vesting on each approximate anniversary of the grant date. After this award, Silver directly holds 441,570 shares of the company’s Common Stock.
Ironwood Pharmaceuticals ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 15,028,000 shares of Class A common stock, representing 9.22% of the class in Amendment No. 6.
The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over the reported securities. The Master Fund disclaims beneficial ownership by virtue of the Investment Management Agreement. The joint filing is signed by Steven Boyd on May 15, 2026.
Ironwood Pharmaceuticals files Amendment No. 1 to a Schedule 13G/A disclosing that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation beneficially own 8,061,073 shares of Class A common stock, representing 4.90% of the class. The filing lists sole voting and sole dispositive power over those shares.
Ironwood Pharmaceuticals announced that Senior Vice President and Chief Financial Officer Gregory Martini will resign effective May 15, 2026. The company states his resignation is not due to any disagreement regarding its financial reporting.
Effective the same date, Ronald Silver, age 44, currently Senior Vice President, Corporate Controller and Chief Accounting Officer, will also serve as interim chief financial officer and principal financial officer. Silver has held increasing accounting leadership roles at Ironwood since 2018 and previously worked in accounting and audit roles at Eze Software Group and RSM. The filing notes there is no special arrangement or family relationship related to his selection and no related‑party transactions requiring disclosure.
Ironwood Pharmaceuticals reported a sharp turnaround to profitability for the quarter ended March 31, 2026. Total revenues rose to $106.5 million from $41.1 million a year earlier, driven mainly by higher collaborative arrangements revenue from LINZESS in the U.S. and abroad.
Net income reached $40.8 million versus a net loss of $37.4 million in the prior-year quarter, with diluted earnings per share improving to $0.24 from a loss of $0.23. Operating income was $72.6 million compared with a loss of $29.1 million, reflecting higher revenue and lower research and development, selling, general and administrative, and restructuring costs.
Ironwood ended the quarter with $220.5 million in cash and cash equivalents. Liabilities included a $200.0 million tranche of 1.50% convertible senior notes due 2026 and $385.0 million outstanding under a revolving credit facility, contributing to a stockholders’ deficit of $217.1 million. The company continues to focus on LINZESS commercialization and advancing apraglutide through late-stage clinical development for short bowel syndrome with intestinal failure.
Ironwood Pharmaceuticals reported a strong turnaround in the first quarter of 2026, with total revenue of $106,506 (thousands), up from $41,143 (thousands) a year earlier. GAAP net income was $40,773 (thousands) versus a prior-year loss, and adjusted EBITDA reached $76,671 (thousands).
Growth was driven by LINZESS, with U.S. net sales of $272,525 (thousands), reflecting 97% year-over-year growth and 5% demand growth. The company maintained 2026 guidance, including U.S. LINZESS net sales of $1.125–$1.175 billion and adjusted EBITDA above $300 million.
Ironwood highlighted a planned confirmatory Phase 3 trial of apraglutide in short bowel syndrome and an FDA priority review of a LINZESS sNDA in younger pediatric patients, with a PDUFA date set for May 24. Management expects strong first-quarter revenue to support repayment of 2026 convertible notes at maturity in June.
Ironwood Pharmaceuticals is asking stockholders to approve four items at its virtual 2026 annual meeting on June 16, 2026 at 9:00 a.m. Eastern. Investors will vote on electing eight directors to one‑year terms, an advisory say‑on‑pay vote, and ratifying KPMG LLP as 2026 auditors.
A key proposal seeks to amend the Amended and Restated 2019 Equity Incentive Plan to add 10,000,000 more shares for equity awards. The proxy describes a largely independent board, detailed committee structure, director fees and stock‑based retainers, and a pay‑for‑performance program using cash bonuses and PSU/RSU equity tied to total stockholder return.
Bank of America Corporation reports beneficial ownership of 9,962,355 shares (Class A Common Stock) of Ironwood Pharmaceuticals, representing 6.1% of the class. The calculation references 163,058,316 shares outstanding as disclosed in the issuer's Form 10-K as of January 31, 2026. The filing (Schedule 13G/A) was submitted on behalf of Bank of America and certain wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.